You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
绿叶制药(02186.HK)附属博安生物引入3家投资者 投前估值48.50亿元
格隆汇 12-28 12:16

格隆汇12月28日丨绿叶制药(02186.HK)宣布,苏州工业园区新建元三期创业投资企业(有限合伙)、深圳市柏奥瑞思投资合伙企业(有限合伙)及烟台创科新动能投资中心(有限合伙)(统称“投资者”)各自有条件同意作出投资并认购山东博安生物技术有限公司(“山东博安”)的部分注册资本。山东博安为一家于中华人民共和国成立的有限公司,是公司的附属公司。投资乃按山东博安的融资前估值约人民币48.50亿元为基础得出。

山东博安于2013年成立,是一家全面综合性生物制药公司。其专门从事治疗用抗体开发,专注于肿瘤、免疫性、疼痛及内分泌疾病。在过去几年,山东博安在抗体生产、先导优化物、细胞系建立、工艺开发、技术转让、中试生产及商业化生产方面积累了丰富的经验。山东博安的抗体发现活动围绕四个平台展开,即全人抗体转基因小鼠及噬菌体展示技术、双特异性T细胞衔接系统技术、抗体偶联技术及纳米抗体平台。其涵盖靶点验证、抗体发现与开发、化学、制造和控制的全过程。独立一致的研发能力确保抗体品质优、开发速度快及供应商依赖性低。

山东博安已开发出10多个拥有国际知识产权保护的创新抗体和8个生物类似药。生物类似药方面,LY01008(Avastin的生物类似药)已申报中国上市申请;LY06006(Prolia的生物类似药)处于中国III期临床及欧美I期临床;LY09004(Eylea的生物类似药)及LY01011(Xgeva的生物类似药)处于中国III期临床。此外,一种创新抗体产品已进入中国I期临床。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account